Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Briquilimab in chronic inducible urticaria
NCT06353971Phase 2Terminated
- Sponsor
- Jasper Therapeutics, Inc.
- Start
- Mar 2024
- Primary completion
- Jul 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of briquilimab in chronic inducible urticaria (CIndU), sponsored by Jasper Therapeutics, Inc.. Started Mar 2024; status: terminated.
02
Drugs
briquilimab
03
Conditions
chronic inducible urticaria (CIndU)
Beyond the preview
Go deeper on NCT06353971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06353971.